These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 21132731

  • 1. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.
    Crowley LC, Elzinga BM, O'Sullivan GC, McKenna SL.
    Am J Hematol; 2011 Jan; 86(1):38-47. PubMed ID: 21132731
    [Abstract] [Full Text] [Related]

  • 2. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
    Elzinga BM, Nyhan MJ, Crowley LC, O'Donovan TR, Cahill MR, McKenna SL.
    Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
    [Abstract] [Full Text] [Related]

  • 3. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 4. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 5. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
    Lavallard VJ, Pradelli LA, Paul A, Bénéteau M, Jacquel A, Auberger P, Ricci JE.
    Cancer Res; 2009 Apr 01; 69(7):3013-20. PubMed ID: 19318579
    [Abstract] [Full Text] [Related]

  • 6. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R, Gandhi V, Plunkett W.
    Cancer Res; 2006 Nov 15; 66(22):10959-66. PubMed ID: 17108134
    [Abstract] [Full Text] [Related]

  • 7. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grünebach F, Brossart P.
    Cancer Res; 2007 Jun 01; 67(11):5489-97. PubMed ID: 17545631
    [Abstract] [Full Text] [Related]

  • 8. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
    Czechowska A, Poplawski T, Drzewoski J, Blasiak J.
    Chem Biol Interact; 2005 Apr 15; 152(2-3):139-50. PubMed ID: 15840387
    [Abstract] [Full Text] [Related]

  • 9. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Ebos JM, Tran J, Master Z, Dumont D, Melo JV, Buchdunger E, Kerbel RS.
    Mol Cancer Res; 2002 Dec 15; 1(2):89-95. PubMed ID: 12496355
    [Abstract] [Full Text] [Related]

  • 10. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.
    Mutat Res; 2006 Jan 31; 603(1):74-82. PubMed ID: 16388976
    [Abstract] [Full Text] [Related]

  • 11. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M.
    Cancer; 2004 Apr 01; 100(7):1459-71. PubMed ID: 15042680
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias.
    Kamitsuji Y, Kuroda J, Kimura S, Toyokuni S, Watanabe K, Ashihara E, Tanaka H, Yui Y, Watanabe M, Matsubara H, Mizushima Y, Hiraumi Y, Kawata E, Yoshikawa T, Maekawa T, Nakahata T, Adachi S.
    Cell Death Differ; 2008 Nov 01; 15(11):1712-22. PubMed ID: 18617896
    [Abstract] [Full Text] [Related]

  • 16. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ, Kim MJ, Kim HB, Kang CD, Kim SH.
    Biochem J; 2009 Apr 28; 420(1):73-81. PubMed ID: 19203346
    [Abstract] [Full Text] [Related]

  • 17. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
    Wei W, Huang H, Zhao S, Liu W, Liu CX, Chen L, Li JM, Wu YL, Yan H.
    Apoptosis; 2013 Sep 28; 18(9):1060-70. PubMed ID: 23613107
    [Abstract] [Full Text] [Related]

  • 18. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
    Stiewe T, Parssanedjad K, Esche H, Opalka B, Pützer BM.
    Cancer Res; 2000 Jul 15; 60(14):3957-64. PubMed ID: 10919674
    [Abstract] [Full Text] [Related]

  • 19. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K.
    Cancer Res; 2003 Aug 15; 63(16):5126-35. PubMed ID: 12941844
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.